Introduction: Multifocal lung cancer is an increasingly common clinical scenario, but there is lack of high-level evidence for its optimal treatment. Thus, we surveyed members of the interdisciplinary International Association for the Study of Lung Cancer on their therapeutic approaches and analyzed the resultant practice patterns.
Methods:
We described the clinical scenario of an otherwise healthy 60-year-old man with bilateral pulmonary nodules and asked the 6373 members of the International Association for the Study of Lung Cancer whether they would recommend surgery, and if so, the extent of surgery. We also asked what other measures would be recommended to complete the staging and whether radiation therapy or chemotherapy would be suggested.
Results:
We received 221 responses (response rate 3.5%) from multiple specialists. Most respondents (140 [63%]) recommended surgery for this scenario. Surgeons were significantly more likely to recommend surgery than were those in other specialties. Of those who recommended surgery, most would obtain a PET/CT scan to rule out distant metastases and a magnetic resonance imaging scan to rule out brain metastases; but in the absence of radiographic lymph node involvement, most would not stage the mediastinum by bronchoscopy or mediastinoscopy before resection. When surgery was not recommended or declined, respondents commonly recommended radiation.
Conclusions: This survey suggests that therapeutic recommendations for multifocal lung cancer are influenced to a large extent by physicians' specialty training, probably because of the lack of high-level evidence for its standard treatment. Ongoing systematic and multidisciplinary approaches with robust short-term and long-term patient outcomes may improve the quality of evidence for the optimal management of this clinical entity.
Introduction
The incidence of multifocal lung cancer (MFLC) is reported in the literature to be 0.2% to 20%, 1, 2 and it has increased with the use of multislice spiral computed tomography (CT) and positron emission tomography (PET) scanning. 3 With the adoption of low-dose CT for lung cancer screening of high-risk groups, the detection of MFLC is expected to further increase. MFLC is a challenging clinical scenario that requires physicians to distinguish multiple primary cancers from intrapulmonary metastases. Current guidelines are limited by our diagnostic uncertainty of the relationship between multiple lesions. On the basis of patient referrals to our institution and discussions with colleagues, we suspected that there are highly divergent practice patterns for MFLC. We sought to survey approaches to management of MFLC among members of the interdisciplinary International Association for the Study of Lung Cancer (IASLC) to understand variations in practice patterns.
Methods
A questionnaire was developed with Research Electronic Data Capture (REDCap) tools to assess how a hypothetical patient with synchronous MFLC would be evaluated and treated. Data were collected and managed by using REDCap tools hosted at Mayo Clinic in Rochester, Minnesota. 4 REDCap is a secure, web-based application designed to support data capture for research studies and providing (1) an intuitive interface for validated data entry, (2) audit trails for tracking data manipulation and export procedures, (3) automated export procedures for seamless data downloads to common statistical packages, and (4) procedures for importing data from external sources.
The following scenario was presented. An otherwise healthy 60 year-old male with a 20-pack-year history of cigarette use who quit smoking 10 years ago is being followed for incidentally discovered indeterminate pulmonary nodules. His most recent CT scan identified a 1.7-cm solid nodule in the anterior segment of the right upper lobe that was 0.7 cm 6 months ago on the initial CT scan. In addition, he was found to have three semisolid lesionstwo in the right lower lobe (a 5-mm lesion in the anterior segment [80% solid] and a 15-mm lesion in the posterior segment [20% solid]) and a 7-mm lesion in the left upper lobe-as well as a 10-mm pure ground glass opacity in the left lower lobe. All these additional nodules have been stable in size and density. There is no adenopathy. His pulmonary function tests (spirometry and diffusing capacity) are within normal limits.
We asked participants whether they would recommend surgery in this scenario, and if so, the extent of surgery. We also asked what other measures would be recommended to complete the staging, and whether radiation therapy or chemotherapy would be suggested if surgery was not recommended or declined. The entire survey can be found in Supplementary Data 1.
On June 24, 2016, the survey was sent by email to 6373 members of the IASLC, and responses were collected for 3 weeks. The responses were summarized with descriptive statistics and compared by medical specialty using the c 2 test. This study was approved by the Mayo Clinic Institutional Review Board.
Results
We received 221 responses from multiple specialists (response rate 3.5%). The specialties and years of experience of the responders are shown in Table 1 
Discussion
Although most respondents favored surgery for MFLC when feasible, many were uncertain as to the optimal approach for this disease. The results of our survey confirm our initial suspicion that specialty may bias the treatment of MFLC. We postulate that this bias exists because of the lack of high-level evidence for the treatment of this clinical entity. Recent patient series have suggested that surgery for patients with MFLC is associated with relatively good 5-year survival outcomes. [5] [6] [7] [8] [9] The fact that there is mainly surgical literature showing the benefit of surgical resection in these cases may be the reason why surgeons are more prone to suggest resection on the basis of clinical application of the available literature.
Two-thirds of all respondents favored utilization of genomic data to more definitively distinguish primary lesions from intrapulmonary metastases; however, the mechanism of genomic testing to determine this distinction is still under debate and was recently reviewed by the IASLC. The use of mutations KRAS and EGFR was reported to determine whether separate lesions were related and concluded that they were related in almost two-thirds of cases and not in almost one-third. 10 Other methods of genetic classification have been attempted, as summarized in recent IASLC Lung Cancer Staging Project publications, but they are concerning on account of the rates of misclassification. 11, 12 Given the fact that few features are definitive to distinguish two foci as separate primary lung cancers versus a metastasis, review by a multidisciplinary tumor board considering all available information is recommended by the IASLC panel.
Also, caution must be applied when determining the relatedness of multiple lesions from mutation panels, which by definition were established on the basis of common occurrence in lung cancer and thereby have a significant probability of random co-occurrence by chance or common occurrence from germline variations. Conversely, a call of independence from a gene panel is restricted by the limited scope of genes and genetic variations to call relatedness. Given these recommendations from the IASLC and the difficulties applying gene panel tests to these patients, our group has standardized our approach to MFLC to improve our understanding of this clinical scenario. In our relevant clinical trials at Mayo Clinic (NCT01946100 and NCT02705404) we utilize a multimodality assessment and treatment protocol, using aggressive local and targeted systemic therapy for individualized treatment of MFLC. Our efforts have focused on cost-effective whole genome approaches to genetic sequencing to provide complete structural profiles of tumors so as to more definitively call relatedness. Through these efforts we have shown that separate primary lesions can be distinguished from intrapulmonary metastases by using genomic approaches, 13 programmed death ligand 1 expression is heterogenous in MFLC, 14 and imaging of the head (preferably by MRI) is a useful adjunct to detecting metastases. 15 Tumor heterogeneity may also affect the appropriate classification of MFLC. 16 Additional merits to whole genome structural profiling of MFLC nodules for measures of tumor lineage arise from the ability to clinically assess the level of relatedness in metastatic lesions. Although two MFLC nodules may be demonstrated to be related, progressive mutations of each distal lesion could lead to a scenario in which despite shared clonal lineage, the repertoire of distinct mutations could result in differential responses to systemic therapies. In this case, management of these clonally related lesions as independent primaries may be recommended. Until stronger evidence-based guidelines are available, we strongly consider the use of local therapies such as surgery 17 or radiation 18 when evidence for systemic (extrapulmonary) spread of disease cannot be identified.
Even though our survey has not focused on the staging and terminology used in patients with multiple lung lesions, it is important to emphasize that the IASLC has put together a committee to conduct a systematic literature review to build an evidence base regarding such tumors and develop proposals for TNM classification used in patients with multiple lung lesions. 19 The term multifocal ground glass/lepidic lung adenocarcinoma is used for multiple discrete nodules of lung cancer that have ground glass features (either pure or part solid) on imaging or lepidic features on histologic examination (with or without an invasive component). This term is not to be used for completely solid lesions. Accordingly, our clinical scenario would be a case of a solid lung cancer and additional ground glass/lepidic features. Implementation of these proposed criteria in the TNM system will overcome the current difficulties in staging of these patients.
We believe that our study has a number of limitations. First, the response rate to our survey was 3.5%, and this is something that we could not control. Second, because of the length limitations of our questionnaire, we did not address questions such as the need for tissue biopsy before radiation therapy or chemotherapy. Indeed, this is a topic in relation to which plenty of questions could be added, and these could be the topic of a separate survey.
These are not the first survey results published on multiple lung lesions. Previous studies have shown that even clinicians with a focus on lung cancer, including pathologists, differ markedly in interpretation of the stage classification rules when it comes to multiple pulmonary foci of lung cancer. 20, 21 Despite this, to our knowledge, our survey is the largest effort to capture the practice patterns on the treatment of a patient with multiple lung lesions.
Conclusion
This survey suggests that therapeutic recommendations for MFLC are influenced by physicians' specialty training, probably because of the lack of high-level evidence for its standard treatment. As MFLC is positioned to become an increasingly common clinical scenario in the era of low-dose CT screening for lung cancer, larger studies focusing on this population and ongoing systematic and multidisciplinary approaches with robust short-term and long-term patient outcomes may improve the quality of evidence for the optimal management of this clinical entity. 
